Skip to content

MBCT for Psoriasis Patients With Anxiety and Depression

Mindfulness-based Cognitive Therapy for Psoriasis Patients With Anxiety and Depression

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05010044
Enrollment
60
Registered
2021-08-18
Start date
2021-08-31
Completion date
2022-01-31
Last updated
2021-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

This study investigates the effectiveness of a 24-week mindfulness intervention in reducing symptoms in psoriasis patients with anxiety and depression.

Detailed description

An adapted MBCT intervention will be offered to people with psoriasis with depression and/or anxiety. 8-week long MBCT therapy will be held between August 2021 and Jan 2022, based on the adapted protocol. The MBCT intervention will consist of 30-minute weekly groups focused on teaching mindfulness techniques and ways to recognize cognitive patterns that can increase anxiety and/or depression. Participants will be recruited from the community, according to the eligibility criteria detailed below. For all participants, anxiety and/or depressive symptom severity(SAS/SDS), PASI,DLQI,(as measured with standardized, validated scales) will be compared baseline and weeks 2;4;8;12;16;20;24. Itch intensity ,itch perception ,quality of sleep, hours missing at work ,helpfulness of common itch therapies serve as the secondary outcome, using a paired t-test.

Interventions

Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.

OTHERAntipsoriatic treatment

The routine drug therapy for psoriasis.

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* the age ranged from 18 to 70 years old * fulfilled the Classification Criteria for Psoriasis * the score of the SDS \> 50 and / or SAS \>50 * Participant has normal or corrected to normal vision and hearing * Participant is willing and able to give informed consent for participation in the study.

Exclusion criteria

* Participant has insufficient manual dexterity for the computerized tasks * severe systemic diseases * patients with severe mental illness or taking psychotic drugs * Pregnancy * No access to the internet

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline on the Psoriasis Area and Severity Index (PASI)Baseline and Week 2;4;8;12;16;20;24PASI a measurement that combines severity of lesions and the area affected in one score that ranges from 0 to 72 .
Change from Baseline on the Dermatology Life Quality Index (DLQI)Baseline and Week 2;4;8;12;16;20;24The DLQI is a 10-item questionnaire measuring the effect of dermatological diseases on patients over the last week. The DLQI total score is the sum of each individual item score and ranges from 0 or 1 to 30 .
Change from Baseline on the Self-rating Depression Scale (SDS)Baseline and Week 2;4;8;12;16;20;24In the main component of the SDS , patients are asked 20 questions about Mental and physical feelings of emotional experience, and the patients determine the quality of emotion by selecting one of the options: Occasionally=1, sometimes=2, often=3, and continuously=4.
Change from Baseline on the Self-rating Anxiety Scale (SAS).Baseline and Week 2;4;8;12;16;20;24In the main component of the SAS , patients are asked 20 questions about Mental and physical feelings of emotional experience, and the patients determine the quality of emotion by selecting one of the options: Occasionally=1, sometimes=2, often=3, and continuously=4. The total score is multiplied by an integer of 1.25 to get the standard score.

Secondary

MeasureTime frameDescription
Hours missing at workBaseline and Week 2;4;8;12;16;20;24Approximate average hours missing at work due to itch per week from last visit.
Helpfulness of common itch therapiesBaseline and Week 2;4;8;12;16;20;24Questions regarding helpfulness of common itch therapies.
Itch perceptionBaselineQuestions regarding situations in which the itch is especially bad (multiple choice options regarding day time, daily situations); objective assessment in which respondents are asked to select answers from the choices offered as a list

Countries

China

Contacts

Primary ContactYan Zhou, professor
yanzhou7798@xjtu.edu.cn0086-13379007762
Backup ContactYan Zhao
2130315198@stu.xjtu.edu.cn0086-18626973745

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026